| Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer (NCT04633239) | National Cancer Institute (NCI) | 2021-07-02 |
| Assessing Sleep and Circadian Rhythms in Primary Brain Tumors Patients (NCT04669574) | National Cancer Institute (NCI) | 2021-06-29 |
| Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer (NCT04579224) | National Cancer Institute (NCI) | 2021-06-28 |
| APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation (NCT04858334) | National Cancer Institute (NCI) | 2021-06-22 |
| Immune Checkpoint Inhibitor M7824 and the Immunocytokine M9241 in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Advanced Pancreas Cancer (NCT04327986) | National Cancer Institute (NCI) | 2021-06-15 |
| Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma (NCT04840615) | National Cancer Institute (NCI) | 2021-06-11 |
| Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents (NCT04739800) | National Cancer Institute (NCI) | 2021-06-10 |
| Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors (NCT04616534) | National Cancer Institute (NCI) | 2021-06-01 |
| Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers (NCT04802174) | National Cancer Institute (NCI) | 2021-06-01 |
| Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma (NCT04609046) | National Cancer Institute (NCI) | 2021-05-24 |
| Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer (NCT04585958) | National Cancer Institute (NCI) | 2021-05-21 |
| Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer (NCT04108858) | National Cancer Institute (NCI) | 2021-05-20 |
| Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma (NCT04799275) | National Cancer Institute (NCI) | 2021-05-20 |
| Systematically Assessing Changes in Plexiform Neurofibroma Related Disfigurement From Photographs of Subjects With Neurofibromatosis Type 1 on a Phase 2 Clinical Trial (NCT04879160) | National Cancer Institute (NCI) | 2021-05-12 |
| Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study (NCT04500548) | National Cancer Institute (NCI) | 2021-05-11 |
| Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease (NCT04294641) | National Cancer Institute (NCI) | 2021-05-10 |
| Review of Post-Study Clinical Endoscopy Reports in Follow Up to MAY2016-07-01 (NCT04674228) | National Cancer Institute (NCI) | 2021-05-07 |
| BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT) (NCT04296942) | National Cancer Institute (NCI) | 2021-05-04 |
| Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial (NCT04320888) | National Cancer Institute (NCI) | 2021-05-03 |
| Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST) (NCT04595747) | National Cancer Institute (NCI) | 2021-05-03 |
| A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy (NCT04847050) | National Cancer Institute (NCI) | 2021-04-28 |
| Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has Spread (NCT04631029) | National Cancer Institute (NCI) | 2021-04-27 |
| Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma (NCT04671667) | National Cancer Institute (NCI) | 2021-04-27 |
| Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations (NCT04550494) | National Cancer Institute (NCI) | 2021-04-26 |
| Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer (NCT04216316) | National Cancer Institute (NCI) | 2021-04-14 |
| Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer (NCT03606967) | National Cancer Institute (NCI) | 2021-04-13 |
| Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers (NCT04460937) | National Cancer Institute (NCI) | 2021-04-09 |
| Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment (NCT04541017) | National Cancer Institute (NCI) | 2021-04-06 |
| Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome (NCT04431024) | National Cancer Institute (NCI) | 2021-03-30 |
| Immersive Virtual Reality (VR) at the Time of Clinical Evaluation to Improve Psychological Distress and Anxiety in Primary Brain Tumor (PBT) Patients (NCT04301089) | National Cancer Institute (NCI) | 2021-03-18 |
| Testing the Addition of a Radiation Sensitizing Drug, IPdR, to the Usual Chemotherapy Treatment (Capecitabine) During Radiation Therapy for Rectal Cancer (NCT04406857) | National Cancer Institute (NCI) | 2021-03-17 |
| A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial (NCT04216290) | National Cancer Institute (NCI) | 2021-03-17 |
| Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer (NCT04394858) | National Cancer Institute (NCI) | 2021-03-17 |
| Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma (NCT03937830) | National Cancer Institute (NCI) | 2021-03-10 |
| Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor (NCT04616560) | National Cancer Institute (NCI) | 2021-03-08 |
| Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study (NCT04269902) | National Cancer Institute (NCI) | 2021-03-02 |
| Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer (NCT04345913) | National Cancer Institute (NCI) | 2021-03-01 |
| Incidence of Malignant Peripheral Nerve Sheath Tumor (MPNST) Development in Participants With Neurofibromatosis Type 1 (NF1) Receiving and Not Receiving Medical Therapies Directed at Plexiform Neurofibromas (PN) (NCT04774289) | National Cancer Institute (NCI) | 2021-02-24 |
| A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer (NCT04633252) | National Cancer Institute (NCI) | 2021-02-23 |
| Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations (NCT04548752) | National Cancer Institute (NCI) | 2021-02-22 |
| BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia (NCT04214249) | National Cancer Institute (NCI) | 2021-02-17 |
| BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia (NCT04284787) | National Cancer Institute (NCI) | 2021-02-16 |
| A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma (NCT04576117) | National Cancer Institute (NCI) | 2021-02-16 |
| NIH-AARP Diet and Health Secondary Research Study Based on OH95CN025 Data (NCT04750915) | National Cancer Institute (NCI) | 2021-02-09 |
| Assessment of Bone Mineral Density in People Living With HIV and KSHV Associated Malignancies: A Retrospective Longitudinal Analysis (NCT04742387) | National Cancer Institute (NCI) | 2021-02-04 |
| Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia (NCT04190550) | National Cancer Institute (NCI) | 2021-02-04 |
| Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated or Viral Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab (NCT04536922) | National Cancer Institute (NCI) | 2021-01-27 |
| Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults (NCT04530565) | National Cancer Institute (NCI) | 2021-01-25 |
| E7 TCR T Cell Induction Immunotherapy for Stage IIB-IVA Cervical Cancer (NCT04476251) | National Cancer Institute (NCI) | 2021-01-14 |
| Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients (NCT04310020) | National Cancer Institute (NCI) | 2021-01-13 |
| Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer (NCT04172532) | National Cancer Institute (NCI) | 2021-01-11 |
| Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial (NCT04402788) | National Cancer Institute (NCI) | 2021-01-07 |
| Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant (NCT04322383) | National Cancer Institute (NCI) | 2021-01-07 |
| Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer (NCT04181060) | National Cancer Institute (NCI) | 2020-12-28 |
| Bintrafusp Alfa (M7824) in Subjects With Thymoma and Thymic Carcinoma (NCT04417660) | National Cancer Institute (NCI) | 2020-12-26 |
| A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden (NCT04145115) | National Cancer Institute (NCI) | 2020-12-24 |
| Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis (NCT04557969) | National Cancer Institute (NCI) | 2020-12-18 |
| Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies (NCT04447027) | National Cancer Institute (NCI) | 2020-12-17 |
| A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL) (NCT04546399) | National Cancer Institute (NCI) | 2020-12-17 |
| Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer (NCT04458909) | National Cancer Institute (NCI) | 2020-12-09 |
| Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT) (NCT04574583) | National Cancer Institute (NCI) | 2020-11-24 |
| Natural History Study of Children and Adults With Neuroendocrine Neoplasms (NEN)s (NCT04488263) | National Cancer Institute (NCI) | 2020-11-24 |
| Mobile Sensor Technologies to Assess General Symptomology of People With Cancer (NCT04465214) | National Cancer Institute (NCI) | 2020-11-23 |
| EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patients (NCT04444921) | National Cancer Institute (NCI) | 2020-11-17 |
| Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer (NCT03641313) | National Cancer Institute (NCI) | 2020-11-16 |
| National Cancer Institute "Cancer Moonshot Biobank" (NCT04314401) | National Cancer Institute (NCI) | 2020-11-11 |
| Testing the Addition of Nivolumab to Chemotherapy in Treatment of Soft Tissue Sarcoma (NCT04339738) | National Cancer Institute (NCI) | 2020-11-04 |
| Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes (NCT03375307) | National Cancer Institute (NCI) | 2020-11-03 |
| Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL (NCT04324112) | National Cancer Institute (NCI) | 2020-10-28 |
| Machine Learning to Analyze Facial Imaging, Voice and Spoken Language for the Capture and Classification of Cancer/Tumor Pain (NCT04442425) | National Cancer Institute (NCI) | 2020-10-27 |
| Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors (NCT04222413) | National Cancer Institute (NCI) | 2020-10-27 |
| Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer (NCT04250545) | National Cancer Institute (NCI) | 2020-10-26 |
| A Phase II Study of Bintrafusp Alfa (M7824) in Checkpoint Inhibitor Naive and Refractory Subjects With Urothelial Carcinoma (NCT04501094) | National Cancer Institute (NCI) | 2020-10-26 |
| Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy (NCT04071236) | National Cancer Institute (NCI) | 2020-10-14 |
| Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial (NCT04284774) | National Cancer Institute (NCI) | 2020-10-13 |
| Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma (NCT04458922) | National Cancer Institute (NCI) | 2020-10-05 |
| Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer (NCT04052555) | National Cancer Institute (NCI) | 2020-09-24 |
| Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal Cancers (NCT04491955) | National Cancer Institute (NCI) | 2020-09-22 |
| Radium-223 in Biochemically Recurrent Prostate Cancer (NCT04206319) | National Cancer Institute (NCI) | 2020-09-22 |
| Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity (NCT04339777) | National Cancer Institute (NCI) | 2020-09-22 |
| Testing of the Addition of a New Anti-cancer Drug, Molibresib, to Chemotherapy Treatment (Etoposide and Cisplatin) for Patients With NUT Carcinoma (NCT04116359) | National Cancer Institute (NCI) | 2020-09-18 |
| Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymphomas (NCT03925428) | National Cancer Institute (NCI) | 2020-09-18 |
| En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device (NCT04235764) | National Cancer Institute (NCI) | 2020-09-09 |
| Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma (NCT04340843) | National Cancer Institute (NCI) | 2020-09-08 |
| Integrated Genomic Prostate Score With MRI Targeted Prostate Biopsies (NCT04541030) | National Cancer Institute (NCI) | 2020-09-02 |
| Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma (NCT04396860) | National Cancer Institute (NCI) | 2020-09-01 |
| Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer (NCT04294628) | National Cancer Institute (NCI) | 2020-09-01 |
| Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel (NCT04449549) | National Cancer Institute (NCI) | 2020-08-24 |
| Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer (NCT04214262) | National Cancer Institute (NCI) | 2020-08-13 |
| HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers (NCT04432597) | National Cancer Institute (NCI) | 2020-08-11 |
| VB-111 in Combination With Nivolumab in People With Metastatic Colorectal Cancer (mCRC) (NCT04166383) | National Cancer Institute (NCI) | 2020-08-09 |
| Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors (NCT04079712) | National Cancer Institute (NCI) | 2020-08-06 |
| Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones (NCT04090398) | National Cancer Institute (NCI) | 2020-08-04 |
| Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation (NCT03953898) | National Cancer Institute (NCI) | 2020-08-04 |
| Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study (NCT04071223) | National Cancer Institute (NCI) | 2020-07-29 |
| Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial) (NCT04195555) | National Cancer Institute (NCI) | 2020-07-20 |
| Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors (NCT04234568) | National Cancer Institute (NCI) | 2020-07-20 |
| Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker (NCT04334941) | National Cancer Institute (NCI) | 2020-07-20 |
| Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN (NCT04317105) | National Cancer Institute (NCI) | 2020-07-17 |
| Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies (NCT04235777) | National Cancer Institute (NCI) | 2020-07-13 |